ShapeShapeauthorShapechevroncrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShaperssShape

Baytril 100 Approved for Use Against Bacterial Pneumonia in Swine

26 October 2012, at 10:42am

CANADA - Bayer has received market authorisation for Baytril 100 (enrofloxacin) injectable solution for treating swine respiratory disease (SRD).

This life-saving antimicrobial is bactericidal, killing the major culprits responsible for SRD in swine: Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis. Baytril® 100 is concentration-dependent, not time-dependent, delivering therapeutic drug concentrations to the lung tissues within two hours of a single subcutaneous dose.1 By concentrating where it is needed, Baytril® 100 achieves pharmacokinetic and pharmacodynamic drug ratios associated with both the reduction of bacterial resistance selection and improved treatment success.

Available to veterinarians since 2004 for treating recurring respiratory disease in high risk feedlot cattle, Canadian swine veterinarians can now take advantage of this new tool to help them in their fight against SRD. Pneumonia can reduce pig growth rates by as much as eight percent so veterinarians need products that work quickly to get their patients back to health.

“Left untreated, respiratory disease in pigs causes lung damage and increases mortality, impacting the bottom line,“ said Dr Bruce Kilmer, Bayer HealthCare, Animal Health’s Director of Technical Services & Regulatory Affairs.

“Researchers have found that SRD can increase feed costs by adding up to six additional days to market. Baytril® 100 has been trusted by veterinarians for years and is highly effective for the treatment of SRD.“

Baytril® 100’s proven efficacy in low volume with easy syringeability encourages successful treatment. For swine, the ready-to-use, injectable antimicrobial solution is administered as a single-dose therapy. Baytril® 100 should not be used as a mass medication. The choice of Baytril® 100 as the most appropriate treatment should be confirmed by clinical experience supported, where possible, by pathogen culture and drug susceptibility testing.

Enrofloxacin has demonstrated in vivo activity against Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis, the major pathogenic bacteria associated with SRD. Enrofloxacin is active in vitro against gram-negative and gram-positive bacteria.

For more information on Baytril® 100, contact the Bayer HealthCare, Animal Health technical service line at 1-888-663-5326, or visit www.animalhealth.bayer.ca

Please refer to the product label for precautions and warnings.